Classification and biology of tumour associated stromal cells

Immunology Letters

Volumn 168, Issue 2, 2015, Pages 175-182

  Raffaghello, Lizzia ^a   Dazzi, Francesco ^b  

^a G GASLINI INSTITUTE   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer associated fibroblasts; Fibrocytes; Mesenchymal stem cells; Tumor stroma

Indexed keywords

ARTICLE; BREAST CANCER; CELL FUNCTION; CELL POPULATION; CELLS BY BODY ANATOMY; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; COLON CARCINOMA; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; EWING SARCOMA; FIBROBLAST; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MESENCHYMAL STROMA CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; STROMA CELL; TUMOR CELL; TUMOR GROWTH; BIOLOGICAL MODEL; CELL COMMUNICATION; IMMUNOLOGY; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

CELL COMMUNICATION; FIBROBLASTS; HUMANS; IMMUNE SYSTEM; MESENCHYMAL STROMAL CELLS; MODELS, IMMUNOLOGICAL; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84949624886     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.06.016     Document Type: Article

References (112)

1. Marsh T., Pietras K., McAllister S.S. Fibroblasts as architects of cancer pathogenesis. Biochim. Biophys. Acta 2013, 1832:1070-1078.
2. Ohlund D., Elyada E., Tuveson D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 2014, 211:1503-1523.
3. Mishra P., Banerjee D., Ben-Baruch A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukocyte Biol. 2011, 89:31-39.
4. Paulsson J., Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin. Cancer Biol. 2014, 25:61-68.
5. Ha S.Y., Yeo S.Y., Xuan Y.H. The prognostic significance of cancer-associated fibroblasts in esophageal squamous cell carcinoma. PLoS One 2014, 9:e99955.
6. Bello I.O., Vered M., Dayan D. Cancer-associated fibroblasts, a parameter of the tumor microenvironment, overcomes carcinoma-associated parameters in the prognosis of patients with mobile tongue cancer. Oral Oncol. 2011, 47:33-38.
7. Marsh D., Suchak K., Moutasim K.A. Stromal features are predictive of disease mortality in oral cancer patients. J. Pathol. 2011, 223:470-481.
8. Yamashita M., Ogawa T., Zhang X. Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer 2012, 19:170-176.
9. Takenaga K., Nakanishi H., Wada K. Increased expression of S100A4 a metastasis-associated gene, in human colorectal adenocarcinomas. Clin. Cancer Res. 1997, 3:2309-2316.
10. Wikberg M.L., Edin S., Lundberg I.V. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 2013, 34:1013-1020.
11. Shi M., Yu D.H., Chen Y. Expression of fibroblast activation protein in human pancreatic adenocarcinoma and its clinicopathological significance. World J. Gastroenterol. 2012, 18:840-846.
12. Tejada M.L., Yu L., Dong J. Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin. Cancer Res. 2006, 12:2676-2688.
13. Paulsson J., Sjoblom T., Micke P. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 2009, 175:334-341.
14. Utispan K., Thuwajit P., Abiko Y. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer 2010, 9:13.
15. Ito M., Ishii G., Nagai K. Prognostic impact of cancer-associated stromal cells in patients with stage I lung adenocarcinoma. Chest 2012, 142:151-158.
16. Leinonen T., Pirinen R., Bohm J. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol. Histopathol. 2008, 23:693-700.
17. Ishikawa S., Takenaka K., Yanagihara K. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin. Cancer Res. 2004, 10:6579-6585.
18. Saito R.A., Micke P., Paulsson J. Forkhead box F1 regulates tumor-promoting properties of cancer-associated fibroblasts in lung cancer. Cancer Res. 2010, 70:2644-2654.
19. Navab R., Strumpf D., Bandarchi B. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:7160-7165.
20. Chang H.Y., Sneddon J.B., Alizadeh A.A. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004, 2:e7.
21. Pittenger M.F., Mackay A.M., Beck S.C. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
22. Li M., Ikehara S. Bone-marrow-derived mesenchymal stem cells for organ repair. Stem Cells Int. 2013, 2013:132642.
23. Makino S., Fukuda K., Miyoshi S. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest. 1999, 103:697-705.
24. Tropel P., Platet N., Platel J.C. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24:2868-2876.
25. Spees J.L., Olson S.D., Ylostalo J. Differentiation, cell fusion, and nuclear fusion during ex vivo repair of epithelium by human adult stem cells from bone marrow stroma. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2397-2402.
26. Dominici M., Le Blanc K., Mueller I. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
27. Abdi R., Fiorina P., Adra C.N. Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 2008, 57:1759-1767.
28. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78:55-62.
29. Zhou B.O., Yue R., Murphy M.M. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 2014, 15:154-168.
30. Gang E.J., Bosnakovski D., Figueiredo C.A. SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 2007, 109:1743-1751.
31. Barcellos-de-Souza P., Gori V., Bambi F. Tumor microenvironment: bone marrow-mesenchymal stem cells as key players. Biochim. Biophys. Acta 2013, 1836:321-335.
32. Miao Z., Jin J., Chen L. Isolation of mesenchymal stem cells from human placenta: comparison with human bone marrow mesenchymal stem cells. Cell Biol. Int. 2006, 30:681-687.
33. Deng J., Petersen B.E., Steindler D.A. Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells 2006, 24:1054-1064.
34. Tondreau T., Lagneaux L., Dejeneffe M. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004, 72:319-326.
35. Martinez C., Hofmann T.J., Marino R. Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 2007, 109:4245-4248.
36. Woodbury D., Schwarz E.J., Prockop D.J. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 2000, 61:364-370.
37. Sacchetti B., Funari A., Michienzi S. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007, 131:324-336.
38. Mendez-Ferrer S., Michurina T.V., Ferraro F. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
39. Bucala R., Spiegel L.A., Chesney J. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1994, 1:71-81.
40. Curnow S.J., Fairclough M., Schmutz C. Distinct types of fibrocyte can differentiate from mononuclear cells in the presence and absence of serum. PLoS One 2010, 5:e9730.
41. Niedermeier M., Reich B., Rodriguez Gomez M. CD4+T cells control the differentiation of Gr1+monocytes into fibrocytes. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:17892-17897.
42. Choi Y.H., Burdick M.D., Strieter R.M. Human circulating fibrocytes have the capacity to differentiate osteoblasts and chondrocytes. Int. J. Biochem. Cell Biol. 2011, 42:662-671.
43. Zhang H., Maric I., DiPrima M.J. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013, 122:1105-1113.
44. Balmelli C., Alves M.P., Steiner E. Responsiveness of fibrocytes to toll-like receptor danger signals. Immunobiology 2007, 212:693-699.
45. Galligan C.L., Siminovitch K.A., Keystone E.C. Fibrocyte activation in rheumatoid arthritis. Rheumatol. (Oxford) 2010, 49:640-651.
46. van Deventer H.W., Wu Q.P., Bergstralh D.T. C-C chemokine receptor 5 on pulmonary fibrocytes facilitates migration and promotes metastasis via matrix metalloproteinase 9. Am. J. Pathol. 2008, 173:253-264.
47. reg-cell expansion. Eur. J. Immunol. 2014, 44:3307-3319.
48. van Deventer H.W., Palmieri D.A., Wu Q.P. Circulating fibrocytes prepare the lung for cancer metastasis by recruiting Ly-6C+monocytes via CCL2. J. Immunol. 2013, 190:4861-4867.
49. Liu P., Wakamiya M., Shea M.J. Requirement for Wnt3 in vertebrate axis formation. Nat. Genet. 1999, 22:361-365.
50. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112:1776-1784.
51. Ombrato L., Malanchi I. The EMT universe: space between cancer cell dissemination and metastasis initiation. Crit. Rev. Oncog. 2014, 19:349-361.
52. Brabletz T., Jung A., Reu S. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10356-10361.
53. Lamouille S., Xu J., Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15:178-196.
54. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
55. Zeisberg M., Shah A.A., Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 2005, 280:8094-8100.
56. Ansieau S., Bastid J., Doreau A. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 2008, 14:79-89.
57. Cai J., Guan H., Fang L. MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J. Clin. Invest. 2013, 123:566-579.
58. Ghahhari N.M., Babashah S. Interplay between microRNAs and WNT/beta-catenin signalling pathway regulates epithelial-mesenchymal transition in cancer. Eur. J. Cancer 2015.
59. Krampera M., Glennie S., Dyson J. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
60. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
61. Cobbold S.P., Adams E., Farquhar C.A. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:12055-12060.
62. Wang Y., Chen X., Cao W. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol. 2014, 15:1009-1016.
63. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9:628-638.
64. Cuiffo B.G., Campagne A., Bell G.W. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell 2014, 15:762-774.
65. Spaeth E., Klopp A., Dembinski J. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008, 15:730-738.
66. Khakoo A.Y., Pati S., Anderson S.A. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 2006, 203:1235-1247.
67. Qiao L., Xu Z., Zhao T. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008, 18:500-507.
68. Qiao L., Xu Z.L., Zhao T.J. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008, 269:67-77.
69. Lu Y.R., Yuan Y., Wang X.J. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol. Ther. 2008, 7:245-251.
70. Cousin B., Ravet E., Poglio S. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS One 2009, 4:e6278.
71. Secchiero P., Zorzet S., Tripodo C. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS One 2011, 5:e11140.
72. Otsu K., Das S., Houser S.D. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009, 113:4197-4205.
73. Dasari V.R., Kaur K., Velpula K.K. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS One 2010, 5:e10350.
74. Dasari V.R., Velpula K.K., Kaur K. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS One 2010, 5:e11813.
75. Velpula K.K., Dasari V.R., Tsung A.J. Regulation of glioblastoma progression by cord blood stem cells is mediated by downregulation of cyclin D1. PLoS One 2011, 6:e18017.
76. Velpula K.K., Dasari V.R., Tsung A.J. Cord blood stem cells revert glioma stem cell EMT by down regulating transcriptional activation of Sox2 and Twist1. Oncotarget 2012, 2:1028-1042.
77. Ho I.A., Toh H.C., Ng W.H. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 2013, 31:146-155.
78. Wang M.L., Pan C.M., Chiou S.H. Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res. 2012, 72:6051-6064.
79. Tu B., Du L., Fan Q.M. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma. Cancer Lett. 2012, 325:80-88.
80. Ye H., Cheng J., Tang Y. Human bone marrow-derived mesenchymal stem cells produced TGFbeta contributes to progression and metastasis of prostate cancer. Cancer Invest. 2012, 30:513-518.
81. Yan X.L., Fu C.J., Chen L. Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res. Treat. 2012, 132:153-164.
82. Halpern J.L., Kilbarger A., Lynch C.C. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 2011, 308:91-99.
83. Rhodes L.V., Antoon J.W., Muir S.E. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Mol. Cancer 2010, 9:295.
84. Muehlberg F.L., Song Y.H., Krohn A. Tissue-resident stem cells promote breast cancer growth and metastasis. Carcinogenesis 2009, 30:589-597.
85. Kucerova L., Matuskova M., Hlubinova K. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 2010, 9:129.
86. Lin G., Yang R., Banie L. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010, 70:1066-1073.
87. Vallabhaneni K.C., Penfornis P., Dhule S. Extracellular vesicles from bone marrow mesenchymal stem/stromal cells transport tumor regulatory microRNA, proteins and metabolites. Oncotarget 2014.
88. Xu W.T., Bian Z.Y., Fan Q.M. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009, 281:32-41.
89. Karnoub A.E., Dash A.B., Vo A.P. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
90. Block G.J., Ohkouchi S., Fung F. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 2009, 27:670-681.
91. Ohkouchi S., Block G.J., Katsha A.M. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol. Ther. 2012, 20:417-423.
92. Anton K., Banerjee D., Glod J. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One 2012, 7:e35036.
93. Potapova I.A., Gaudette G.R., Brink P.R. Mesenchymal stem cells support migration, extracellular matrix invasion, proliferation, and survival of endothelial cells in vitro. Stem Cells 2007, 25:1761-1768.
94. Rajantie I., Ilmonen M., Alminaite A. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104:2084-2086.
95. Bexell D., Gunnarsson S., Tormin A. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther. 2009, 17:183-190.
96. Annabi B., Lee Y.T., Turcotte S. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells 2003, 21:337-347.
97. Suzuki K., Sun R., Origuchi M. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol. Med. 2011, 17:579-587.
98. Birnbaum T., Hildebrandt J., Nuebling G. Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. J. Neurooncol. 2011, 105:57-65.
99. Spaeth E.L., Dembinski J.L., Sasser A.K. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
100. Kidd S., Spaeth E., Watson K. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012, 7:e30563.
101. Mishra P.J., Mishra P.J., Humeniuk R. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68:4331-4339.
102. Martin F.T., Dwyer R.M., Kelly J. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 2010, 124:317-326.
103. El-Haibi C.P., Bell G.W., Zhang J. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:17460-17465.
104. Jing Y., Han Z., Liu Y. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. PLoS One 2012, 7:e43272.
105. Li H.J., Reinhardt F., Herschman H.R. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2012, 2:840-855.
106. Rappa G., Mercapide J., Lorico A. Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am. J. Pathol. 2012, 180:2504-2515.
107. Yu J.M., Jun E.S., Bae Y.C. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 2008, 17:463-473.
108. Shinagawa K., Kitadai Y., Tanaka M. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int. J. Cancer 2010, 127:2323-2333.
109. Vianello F., Villanova F., Tisato V. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis. Haematologica 2010, 95:1081-1089.
110. Studeny M., Marini F.C., Champlin R.E. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62:3603-3608.
111. Grisendi G., Bussolari R., Cafarelli L. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010, 70:3718-3729.
112. Lathrop M.J., Sage E.K., Macura S.L. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther. 2015, 22:44-54.